CAH•benzinga•
Cardinal Health Executive Says Company Will Actively Evaluate Additional Opportunities To Accelerate Growth In Specialty Therapeutic Areas; GLP-1 Drugs Are Continuing To Contribute To Revenue And Grow More So Than We Had Originally Expected
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 1, 2024 by benzinga